Chimerix, Inc. Announces Selection As a Top 5 Nominee for 2005 World Technology Award in Health and Medicine
Posted on: Thursday, 10 November 2005, 09:00 CST
RESEARCH TRIANGLE PARK, N.C., Nov. 10 /PRNewswire/ -- Chimerix, Inc., a biotechnology company developing orally available, targeted medicines to treat smallpox and other viral infections, announced today that the company has been selected as one of the top five nominees for this year's World Technology Network (WTN) Award in health and medicine. Criteria for nominee selection include an innovative technology with long-term significance in health and medicine, outstanding executive management leadership, and a technology with the potential to have a global marketplace impact. In addition, Chimerix was named a WTN corporate member, a peer-nominated, peer-selected organization composed of the most innovative people in science and technology.
"One of the greatest challenges facing the healthcare industry today is the increasing emergence of multi-drug resistant viral strains. Chimerix's technology addresses this unmet need through the development of orally available antiviral drug candidates," said George Painter, Ph.D., President and CEO of Chimerix. "We are honored to be chosen for this prestigious nomination among an outstanding group of organizations."
Chimerix's powerful lipid conjugate technology creates drugs with enhanced therapeutic properties, including improved oral availability and increased absorption by cells and target tissues. Application of this technology to known drugs is expected to improve dosing parameters, broaden therapeutic use, and decrease the risk of adverse reactions. Chimerix has leveraged this technology with CMX001, which offers the promise of an oral drug for the treatment of smallpox and complications from smallpox vaccine. Smallpox is a potentially devastating bioterrorism threat and vaccination poses significant risk for those individuals with compromised immune systems or skin disorders.
About Chimerix
Chimerix, Inc. is a privately held biotechnology company creating and developing orally available medicines from bioactive molecules. Application of Chimerix's proprietary technology enhances oral availability, stabilizes drug in plasma, and facilitates the delivery of drugs into targeted tissues. Known drugs can be modified to improve dosing parameters, broaden therapeutic applications and decrease the risk of adverse reactions. Chimerix is applying its technology towards discovery and development of oral drugs for the treatment of smallpox, cytomegalovirus infection, drug-resistant HIV infection and viral hepatitis. Chimerix was founded in 2002 and is located in Research Triangle Park, NC.
Chimerix, Inc.
CONTACT: Amy Beltran, Ph.D., of Atkins + Associates, +1-858-527-3489,abeltran@irpr.com, for Chimerix, Inc.
Source: PRNewswire
Related Articles
- Injecting-drug users risk behaviors high
- CytRx Corporation's 45% Owned Affiliate RXi Pharmaceuticals Obtains an Exclusive Worldwide License to Technology for the Oral Delivery of RNAi Therapeutics From the University of Massachusetts Medical School
- RXi Pharmaceuticals Obtains an Exclusive Worldwide License to Technology for the Oral Delivery of RNAi Therapeutics From the University of Massachusetts Medical School
- Examine Injectable Drug Delivery Technologies, Targets and Therapeutics With This Essential and Comprehensive Report
- Xanthus Receives Orphan Drug Designation for Oral Fludarabine for the Treatment of CLL
- 2006 Nobel Prize Winner to Deliver Keynote Address at IBC's 12th Annual Drug Discovery & Development of Innovative Therapeutics World Congress
- Siga Gets NIH Grant for Smallpox Drug Development
- Positive First Human Trial for Siga Smallpox Drug
- FDA Approves SIGA's Investigational New Drug Application for Its Smallpox Drug SIGA-246
- Research and Markets: Phosphodiesterases: A Drug Target Family With Broad Therapeutic Impact
 |
 |
User Comments (0)
RSS Feeds